Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2009 Jun;70(3):228–239. doi: 10.1016/j.curtheres.2009.05.002

Pharmacokinetic properties of lansoprazole (30-mg enteric-coated capsules) and its metabolites: A single-dose, open-label study in healthy Chinese male subjects

Min Song 1, Xuan Gao 1, Tai-Jun Hang 1, Ai-Dong Wen 2,*
PMCID: PMC3967358  PMID: 24683233

Abstract

Background: Lansoprazole, a benzimidazole derivative, is indicated for the treatment of various peptic diseases. It is metabolized mainly in the liver, and its primary active metabolites present in plasma are 5′-hydroxy lansoprazole and lansoprazole sulfone. Few data are available on the pharmacokinetic properties of lansoprazole, 5′-hydroxy lansoprazole, and lansoprazole sulfone, which can be used to measure cytochrome P450 (CYP) 2C19 activity.

Objectives: The aims of this study were to investigate the clinical plasma pharmacokinetic properties of lansoprazole and its metabolites in healthy Chinese male volunteers, and to assess the influences of CYP2C19 on the pharmacokinetics of lansoprazole.

Methods: Healthy adult Chinese male volunteers were enrolled in this single-dose, open-label study. All patients received a single oral enteric capsule containing 30 mg of lansoprazole after a 12-hour overnight fast. Serial blood samples were collected immediately before (0 hour) and at 20, 40, 60, 90, 120, and 150 minutes and 3, 4, 6, 8, 10, 12, 15, and 24 hours after study drug administration. The plasma concentrations of lansoprazole, 5′-hydroxy lansoprazole, and lansoprazole sulfone were determined using a validated internal standard high-performance liquid chromatography—tandem mass spectrometry (HPLC-MS/MS) method. Pharmacokinetic properties (including Cmax, Tmax, elimination t½ [t½z], mean residence time [MRT], AUC0–24, AUC0−∞, apparent oral clearance [CLz/F], and apparent volume of distribution [Vz/F]) were determined using the noncompartmental method.

Results: Twenty volunteers (mean [SD] age, 34.9 [2.9] years; weight, 64.6 [2.2] kg; height, 171.3 [3.3] cm) were enrolled in and completed the study. The mean (SD) pharmacokinetic properties of lansoprazole were as follows: Cmax, 1047 (344) ng/mL; Tmax, 2.0 (0.7) hours; t½z, 2.24 (1.43) hours; MRT, 3.62 (0.87) hours; AUC0−24, 3388 (1484) ng/mL/h; AUC0-∞, 3496 (1693) ng/mL/h; CLz/F, 9.96 (3.74) L/h; and Vz/F, 32.83 (11.74) L. The findings with 5′-hydroxy lansoprazole and lansoprazole sulfone, respectively, were as follows: Cmax, 111.2 (41.8) and 66.6 (52.9) ng/mL; Tmax, 2.1 (0.8) and 1.9 (0.8) hours; t½z, 2.31 (1.18) and 2.52 (1.54) hours; and AUC0−24, 317.0 (81.2) and 231.9 (241.7) ng/mL/h. No adverse events were reported throughout the study.

Conclusions: In these healthy Chinese male volunteers administered a single oral dose of lansoprazole 30 mg, absorption of lansoprazole was rapid (mean Cmax, 1047 ng/mL; Tmax, ~2.0 hours). Its 2 primary active metabolites, 5′-hydroxy lansoprazole and lansoprazole sulfone, were identified in measurable quantities in plasma (Cmax, 111.2 and 66.6 ng/mL, respectively; and Tmax, 2.1 and 1.9 hours). The plasma t½z did not appear to reflect the duration of suppression of gastric acid secretion: the t½z values of lansoprazole and the 2 metabolites were ~2 to 2.5 hours, while the acid-inhibitory effect lasted >24 hours. Cmax, AUC, and t½z of lansoprazole, and especially lansoprazole sulfone, varied. Differences in metabolism types and/or genotype of CYP2C19 should be taken into account when planning a lansoprazole dosing regimen.

Key words: lansoprazole, 5′-hydroxy lansoprazole, lansoprazole sulfone, pharmacokinetics, HPLC-MS/MS

Full Text

The Full Text of this article is available as a PDF (123.8 KB).

References

  • 1.Fu LQ, Huang F. Determination of lansoprazole and its metabolites 5′-hydroxy lansoprazole and lansoprazole sulfone in human plasma by reversed phase HPLC. Chin J Clin Pharmacol. 2003;8:35–38. [Google Scholar]
  • 2.Barradell BL, Faulds D, Lansoprazole McTavish D. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992;44:225–250. doi: 10.2165/00003495-199244020-00007. [DOI] [PubMed] [Google Scholar]
  • 3.Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole [published correction appears in Clin Pharmacokinet. 1996;31:274] Clin Pharmacokinet. 1996;31:9–28. doi: 10.2165/00003088-199631010-00002. [DOI] [PubMed] [Google Scholar]
  • 4.Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996;277:805–816. [PubMed] [Google Scholar]
  • 5.Sohn DR, Kwon JT, Kim HK, Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther. 1997;61:574–582. doi: 10.1016/S0009-9236(97)90137-5. [DOI] [PubMed] [Google Scholar]
  • 6.Furuta T, Shirai N, Takashima M. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69:158–168. doi: 10.1067/mcp.2001.113959. [DOI] [PubMed] [Google Scholar]
  • 7.Adachi K, Katsube T, Kawamura A, CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000;14:1259–1266. doi: 10.1046/j.1365-2036.2000.00840.x. [DOI] [PubMed] [Google Scholar]
  • 8.Katsuki H, Nakamura C, Arimori K. Genetic polymorphism of CYP2C19 and lansopra-zole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol. 1997;52:391–396. doi: 10.1007/s002280050307. [DOI] [PubMed] [Google Scholar]
  • 9.Jian C, Hu QS. Bioequivalence of lansoprazole enterosoluble tablets and capsules in healthy volunteers. Chin J Clin Pharmacol. 2006;11:558–561. [Google Scholar]
  • 10.Hu YR, Qiao HL, Kan QC. Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes. Acta Pharmacol Sin. 2004;25:986–990. [PubMed] [Google Scholar]
  • 11.Dugger HA, Carlson JD, Henderson W. Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers. Eur J Pharm Biopharm. 2001;51:153–157. doi: 10.1016/s0939-6411(00)00152-1. [DOI] [PubMed] [Google Scholar]
  • 12.Song M, Gao X, Hang TJ, Wen AD. Simultaneous determination of lansoprazole and its metabolites 5′-hydroxy lansoprazole and lansoprazole sulfone in human plasma by LC-MS/MS: Application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal. 2008;48:1181–1186. doi: 10.1016/j.jpba.2008.08.034. [DOI] [PubMed] [Google Scholar]
  • 13.Chen WL, Li XN. Bioequivalence of lansoprazole and its metabolites. Chin J Clin Pharmacy. 2005;14:351–354. [Google Scholar]
  • 14.Prevacid [product information] http://www.fda.gov/cder/foi/label/2008/020406s067,021281s024,021428s017lbl.pdf Accessed October 23, 2008.

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES